Trial Profile
INCB018424 in the Treatment of Cutaneous Lichen Planus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Apr 2024
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Lichen planus
- Focus Therapeutic Use
- 12 Mar 2024 Results assessing the repurposed and optimized the modified Composite Assessment of Index Lesion Severity (mCAILS) for LP using data from NCT03697460 trial and validated the optimized lichen planus CAILS (lpCAILS) using data from NCT05188521 trial, presented at the American Academy of Dermatology annual Meeting 2024.
- 01 Aug 2022 Results published in the Journal of Investigative Dermatology
- 25 Apr 2021 Primary endpoint (lesion count) has been met, as per results presented at the American Academy of Dermatology Virtual Meeting Experience 2021.